Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-05-22
2007-05-22
Campbell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S041000
Reexamination Certificate
active
10838770
ABSTRACT:
Vif binds to APOBEC3G and induces its rapid degradation, thus eliminating it from cells and preventing its incorporation into HIV-1 virions. Vif contains two domains, one that binds APOBEC3G and another with a conserved SLQ(Y/F)LA motif that mediates APOBEC3G degradation by a proteasome-dependent pathway. Provided herein are methods of exploiting these discoveries to develop compounds useful to inhibit Vif degradation of APOBEC3G, and thereby inhibit viral infection and/or replication.
REFERENCES:
patent: 6653443 (2003-11-01), Zhang et al.
patent: 2002/0164743 (2002-11-01), Honjo et al.
patent: 2003/0013844 (2003-01-01), Zang et al.
patent: 2004/0009951 (2004-01-01), Malim et al.
patent: WO 95/05851 (1995-03-01), None
patent: WO 03/095636 (2003-11-01), None
patent: WO 2004/013160 (2004-02-01), None
Harris R. RNA Editing Enzyme APOBEC-1 and Some of its Homologs Can Act as DNA Mutators. Nov. 2002. Molecular Cell, vol. 10, p. 1247-1253.
Kiser R. Assessment of a cytoprotection assay for the discovery and evaluation of anti-HIV compounds utilizing a genetically-imparied virus. 1996. Journal of Virological Methods, vol. 58, p. 99-109.
Barak L. Fluorescent Low Density Lipoprotein for Observation of Dynamics of Inidividual Receptor Complexes on Cultured Human Fribroblasts. Sep. 1981. Journal of Cell Biology, vol. 90, p. 595-604.
Baba, et al., “A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity,”PNAS, 96:5698-5703 (May 1999).
Bogerd, et al., “A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor,”PNAS, 101(11):3770-3774 (Mar. 16, 2004).
Conticello, et al., “The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G,”Current Biology, 13:2009-2013 (Nov. 11, 2003).
Gaddis, et al., “Comprehensive Investigation of the Molecular Defect invif-Deficient Human Immunodeficiency Virus Type 1 Virions,”J. Virology, 77(10):5810-5820 (May 2003).
Harris, et al., “DNA Deamination Mediates Innate Immunity to Retroviral Infection,”Cell, 113:803-809 (Jun. 13, 2003).
Iwai, et al., “Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex,”PNAS, 96(22):12436-12441 (Oct. 26, 1999).
Kao, et al., “The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity,”J. Virology, 77(12):11398-11407 (Nov. 2003).
Lecossier, et al., “Hypermutation of HIV-1 DNA in the Absence of the Vif Protein,”Science, 300:1112 (May 16, 2003).
Liu, et al., “Influence of Primate Lentiviral Vif and Proteasome Inhibitors on Human Immunodeficiency Virus Type 1 Virion Packaging of APOBEC3G,”J. Virology, 78(4):2072-2081 (Feb. 2004).
Madani and Kabat, “An Endogenous Inhibitor of Human Immunodeficiency Virus in Human Lymphocytes is Overcome by the Viral Vif Protein,”J. Virology, 72(12):10251-10255 (Dec. 1998).
Madani and Kabat, “Cellular and Viral Specificities of Human Immunodeficiency Virus Type 1 Vif Protein,”J. Virology, 74(13):5982-5987 (Jul. 2000).
Mangeat, et al., “Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts,”Nature, 424:99-103 (Jul. 3, 2003).
Mangeat, et al., “A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action,”J. Biological Chemistry, 279(15):144481-14483 (2004).
Mariani, et al., “Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif,”Cell, 114:21-31 (Jul. 11, 2003).
Marin, et al., “HIV-1 Vif Protein binds the editing enzyme APOBEC3G and induces its degradation,”Nature Medicine, 9(11):1398-1403 (Nov. 2003).
Mehle, et al., “Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway,”J. Biological Chemistry, 279(9):7792-7798 (Feb. 27, 2004).
Mehta, et al., “Molecular Cloning of Apobec-1 Complementation Factor, a Novel RNA-Binding Protein Involved in the Editing of Apolipoprotein B mRNA,”Molecular and Cellular Biology, 20(9):1846-1854 (Mar. 2000).
Oberste and Gonda, “Conservation of amino-acid sequence motifs in lentivirus Vif proteins,”Virus Genes, 6(1):95-102 (Jan. 1992) Abstract Only.
Rose, et al., “The viral infectivity factor (Vif) of HIV-1 unveiled,”Trends in Molecular Medicine, 10(6):291-297 (Jun. 2004).
Schröfelbauer, et al., “A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif),”PNAS, 101(11):3927-3932 (Mar. 16, 2004).
Sheehy, et al., “The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif,”Nature Medicine, 9(11):1404-1407 (Nov. 2003).
Sheehy, et al., “Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein,”Nature, 418:646-650 (2002).
Shindo, et al., “The Enzymatic Activity of CEM15/Apobec-3G is Essential for the Regulation of the Infectivity of HIV-1 Virion by Not a Sole Determinant of its Antivirial Activity,”J. Biological Chemistry, 278(45):44412-44416 (2003).
Simon, et al., “Evidence for a newly discovered cellular anti-HIV-1 phenotype,”Nature Medicine, 4(12):1397-1400 (Dec. 1998).
Stopak, et al., “HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability,”Molecular Cell, 12:591-601 (Sep. 2003).
Strizki, et al., “SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo,” PNAS, 98(22):12718-12723 (Oct. 23, 2001).
Sonigo, et al., “Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus,”Cell, 42(1):369-82 (Aug. 1985) Abstract Only.
Vartanian, et al., “Death and the retrovirus,”Trends in Molecular Medicine, 9(10):409-413 (Oct. 2003).
Vassilev, et al., “In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2,”Science, 303:844-848 (Feb. 6, 2004).
Xu, et al., “A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion,”PNAS, 101(15):5652-5657 (Apr. 13, 2004).
Yu, et al., “Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex,”Science, 302:1056-1060 (Nov. 7, 2003).
Zhang, et al., “The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA,”Nature, 424:94-98 (Jul. 3, 2003).
Kabat David
Kozak Susan L.
Marin Mariana
Rose Kristine M.
Campbell Bruce R.
Humphrey Louise
Klarquist & Sparkman, LLP
Oregon Health and Science University
LandOfFree
Methods for identifying inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816083